Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrc.2016.51 http://scihub22266oqcxt.onion/10.1038/nrc.2016.51 C5094465!5094465 !27282250     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27282250 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Nat+Rev+Cancer 2016 ; 16 (7 ): 413-30 Nephropedia Template TP {{tp|p=27282250 |t=2016. RNA splicing factors as oncoproteins and tumour suppressors |pdf=|usr=}}{{27282250 }} gab.com Text RNA splicing factors as oncoproteins and tumour suppressors JO: Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=27282250 #FOAvip The recent genomic characterization of cancers has revealed recurrent somatic point mutations and copy number changes affecting genes encoding RNA splicing factors. Initial studies of these 'spliceosomal mutations' suggest that the proteins bearing these mutations exhibit altered splice site and/or exon recognition preferences relative to their wild-type counterparts, resulting in cancer-specific mis-splicing. Such changes in the splicing machinery may create novel vulnerabilities in cancer cells that can be therapeutically exploited using compounds that can influence the splicing process. Further studies to dissect the biochemical, genomic and biological effects of spliceosomal mutations are crucial for the development of cancer therapies targeted at these mutations. Twit Text FOAVip RNA splicing factors as oncoproteins and tumour suppressors ????Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=27282250 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27282250 #FOAvip English Wikipedia <ref>{{Cite pmid|27282250 }}</ref> RNA splicing factors as oncoproteins and tumour suppressors #MMPMID27282250 Dvinge H ; Kim E ; Abdel-Wahab O ; Bradley RK Nat Rev Cancer 2016[Jul]; 16 (7 ): 413-30 PMID27282250 show ga The recent genomic characterization of cancers has revealed recurrent somatic point mutations and copy number changes affecting genes encoding RNA splicing factors. Initial studies of these 'spliceosomal mutations' suggest that the proteins bearing these mutations exhibit altered splice site and/or exon recognition preferences relative to their wild-type counterparts, resulting in cancer-specific mis-splicing. Such changes in the splicing machinery may create novel vulnerabilities in cancer cells that can be therapeutically exploited using compounds that can influence the splicing process. Further studies to dissect the biochemical, genomic and biological effects of spliceosomal mutations are crucial for the development of cancer therapies targeted at these mutations. |*Genes, Tumor Suppressor [MESH] |Catalysis [MESH] |Humans [MESH] |Neoplasms/drug therapy/genetics [MESH] |Oncogene Proteins/*physiology [MESH]RNA splicing factors as oncoproteins and tumour suppressors (epmc).pdf DeepDyve Pubget Overpricing